XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Acadia Pharmaceuticals Inc

Announcement: ACAD 8-K Special Filing

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

ACADIA PHARMACEUTICALS: Trofinetide NDA filed & pimavanserin in Phase 3
Current Analysis:
ACADIA's NUPLAZID® is FDA-approved to treat Parkinson’s disease psychosis. They've submitted to the FDA an NDA for trofinetide for the treatment of Rett syndrome with PDUFA target action on March 12, 2023. Another drug in the pipeline is pimavanserin evaluated in a Phase 3 clinical program for negative symptoms of schizophrenia. ACADIA also announced their internally discovered new molecule, ACP-204, which is currently evaluated in a Phase 1 clinical program.

Forward-Looking Analysis:
ACADIA's NUPLAZID® has a first mover advantage in the US. However, they'll face increasing competition from other antipsychotic therapies. Trofinetide and pimavanserin, if approved, have the potential to create new revenue streams for the company. ACADIA's leveraging strategic R&D partnerships with Stoke to meet their long-term growth objectives. In addition, COVID-19 has disrupted supply chains and clinical trials, and may negatively impact retail investors' short-term prospects.

Announcement: ACAD 10-K Annual Report

Form 8-K - Current report - Item 2.02 Item 9.01

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ACAD 8-K Special Filing

Announcement: ACAD 8-K Special Filing

Announcement: ACAD 10-K Annual Report

Announcement: ACAD 10-K Annual Report

Announcement: ACAD 8-K Special Filing

Announcement: ACAD 8-K Special Filing

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

Announcement: ACAD SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment